What question did this study set out to answer?

This research compares the efficacy and safety of letermovir versus valganciclovir for CMV prophylaxis in liver transplant recipients.

January 14, 2026Open Access

Letermovir as CMV Prophylaxis in Liver Transplant Recipients

Key Points

This research compares the efficacy and safety of letermovir versus valganciclovir for CMV prophylaxis in liver transplant recipients.
Single-center, retrospective cohort study
Included 133 liver transplant patients
Statistical analysis performed using SPSS
Fewer CMV DNAemia breakthroughs on letermovir (8%) compared to valganciclovir (26%)
Lower incidence of neutropenia on letermovir (12% vs. 71%)
No drug discontinuation due to hematological toxicity with letermovir (0% vs. 20%)

Abstract

Abstract Background Letermovir has emerged as a safe and effective antiviral agent for CMV prophylaxis in allogeneic HCT recipients and high-risk kidney transplant recipients. There is a paucity of data on the use of letermovir in liver transplant recipients. This study aims to compare letermovir to valganciclovir in terms of efficacy and safety for CMV prophylaxis in liver transplant recipients.Table 1Baseline Patient CharacteristicsTable 2CMV and Other Clinical Outcomes by CMV Serostatus Methods This single-center, retrospective cohort included all consecutive patients who received a liver transplant between January 1, 2021, and April 30, 2024. Patients who received more than one liver transplant were excluded. Statistical analysis was performed using SPSS.Table 3CMV and Other Clinical Outcomes by Prophylaxis BreakthroughTable 4Prophylaxis Episode Details and Safety Outcomes per Prophylaxis Episode Results A total of 133 patients met inclusion criteria, 42 (32%) were D+/R- and 91 (68%) were R+. All patients had received valganciclovir, and 26 (20%) patients received letermovir, most of whom were transitioned due to an established adverse event on valganciclovir. There were significantly fewer CMV DNAemia breakthroughs on letermovir (2, 8%) than on valganciclovir (34, 26%, p = 0.046) within the first year post-transplant. Only one patient developed CMV disease (colitis) and was on letermovir. The letermovir prophylaxis episodes had significantly fewer events of neutropenia of any grade (12% vs. 71%, p 0.001), neutropenia of grade ≥ 2 (12% vs. 41%, p 0.001), G-CSF use (8% vs. 23%, p = 0.072), and drug discontinuation due to hematological toxicity (0% vs. 20%, p = 0.008), compared to valganciclovir. Conclusion Letermovir is a safer alternative to valganciclovir for CMV prophylaxis, and potentially more effective at suppressing CMV replication, in liver transplant recipients. Large prospective studies are needed to confirm these findings. Disclosures All Authors: No reported disclosures

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Siegrist et al. (Thu,) studied this question.

synapsesocial.com/papers/6966f33b13bf7a6f02c012f7 https://doi.org/https://doi.org/10.1093/ofid/ofaf695.034

KI fragen

Bookmark

View Full Paper